Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
Skinvisible Pharmaceuticals announced promising data on their transdermal obesity formulations using Invisicare technology. The studies showed significant penetration rates: 69% for GLP-1 receptor agonists and 62% for CB-1 receptor antagonists over six hours. Invisicare's formulations also demonstrated sustained drug release, with an average of 10% per hour. These findings suggest that Invisicare can avoid the side effects of oral and injectable obesity drugs, enhancing patient compliance. Skinvisible is seeking strategic partnerships to bring these therapies to market, targeting the growing obesity market projected to reach $131 billion by 2028.
- 69% penetration of GLP-1 receptor agonists over six hours.
- 62% penetration of CB-1 receptor antagonists over six hours.
- Sustained drug release averaging 10% per hour.
- Potential to avoid side effects of oral pills and injections.
- Enhancement of patient compliance with transdermal formulations.
- Seeking strategic partnerships to bring therapies to market.
- Targeting the rapidly growing obesity market, expected to reach $131 billion by 2028.
- None.
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology
LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical pharmaceutical research and development company, today announced exciting data demonstrating its transdermal delivery of obesity drugs (and other glucose- controlling drugs) including a GLP-1 agonist and CB-1 receptor antagonist delivered by its proprietary Invisicare® technology; a polymer delivery vehicle that does not require a patch or needles. The Company previously announced it has filed two provisional patent applications covering formulations that leverage Invisicare for the transdermal administration of obesity drugs and other glucose-controlling agents.
The Company has been developing topical formulations to enable transdermal absorption of these drugs, allowing for sustained release into the bloodstream. The results are compelling:
Franz Cell diffusion studies demonstrated up to
69% penetration over six hours for the GLP-1 drug tested;For the CB-1 antagonists formulated with Invisicare, a
62% penetration rate was achieved over the same time period;In addition to these high penetration rates, these studies demonstrate that Invisicare formulations have the ability to provide sustained drug delivery over time. Data showed an average drug release of approximately
10% per hour.
Building on this breakthrough, Skinvisible is confident that its proprietary technology can be applied to a broader range of GLP-1 agonists and CB-1 receptor antagonists with a molecular mass that permits transdermal penetration. This development opens up exciting possibilities for expanding the company's portfolio of obesity-targeting formulations.
"Our Invisicare technology has the potential to revolutionize how obesity drugs are administered," said Terry Howlett, Skinvisible's CEO. "We can deliver significant amounts of drug systemically, potentially avoiding the side effects of oral pills and injections and increase patient compliance." He explained, "Since pills must pass through the digestive system and liver first, much of the drug is metabolized before reaching its target and may lead to uncomfortable side-effects. Injections can be painful and lead to poor patient compliance. Our topical cream formulations offer a transdermal approach that circumvents first-pass metabolism and related challenges. Furthermore, these transdermal obesity treatments could serve effectively as a maintenance therapy."
Skinvisible has pursued the obesity market due to the overwhelming increase in the need for obesity drugs and treatment options. According to a recent IQVIA report, the prevalence of obesity in the world is expected to be
Skinvisible is actively seeking a strategic partnership with a pharmaceutical and/or biotech company to bring the first transdermal obesity therapies to market and to explore applications of its transdermal delivery platform across other disease areas.
For more information on Skinvisible Pharmaceuticals, partnerships and investment opportunities, please visit www.skinvisible.com or contact info@skinvisible.com.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby including with respect to the possible development of any such products, the acceptance of any such products in the market place, the size of any such markets, the ability of any product candidates to be approved by the U.S. Food and Drug Administration among others. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending March 31, 2024).
###
Contacts:
Strategic Partnerships: Doreen McMorran - doreen@invisicare.com
Corporate Inquiries: info@skinvisible.com
Office Number: 702-433-7154 (PST)
SOURCE: Skinvisible Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What are the penetration rates of SKVI's transdermal obesity drugs?
How does SKVI's Invisicare technology enhance obesity drug delivery?
What are the projected market opportunities for SKVI's obesity treatments?
What strategic moves is SKVI making for their transdermal obesity treatments?
